News

The expansion of the study to the US builds upon Immix’ results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose

Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said: “Anteros Pharmaceuticals

The supplemental New Drug Application (sNDA), which has been filed by the company and accepted by the regulator, is seeking approval for using Recarbrio for treating adult patients

BAT1706 is being developed by Bio-Thera Solutions as a proposed biosimilar to Avastin. The trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients

AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. (Otsuka) as part of a May 2017 exclusive license agreement for development and sales of AJOVY in

Established in 2011, MaSTherCell Global is a technology-focused cell and gene therapy contract development and manufacturing organisation (CDMO) that serves cell therapy innovators. Catalent chair and CEO John

Palforzia, which was formerly known as AR101, has been indicated in the US for the mitigation of anaphylaxis and other allergic reactions following accidental exposure to peanut. The

The application was originally filed in 2018 for patients with first-line NSCLC who have tumor mutational burden ≥10 mutations/megabase, based on the final analysis of progression-free survival, a

RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),